Important Disclosure Information
Blackstone proprietary data as of October 31, 2025, unless otherwise indicated. Represents Blackstone’s view of the current market environment as of the date appearing herein which is subject to change. The figures herein include preliminary, unaudited results, which are subject to further review and adjustment. When used in this presentation and unless otherwise specified or unless the context otherwise requires, references to the “Fund” should be read as references to Blackstone Private Equity Strategies Fund SICAV (“BXPE”), Blackstone Private Equity Strategies Fund (Master) FCP, BXPE Aggregator and their parallel entities. Capitalized terms used but not defined will have the meanings set forth in the prospectus prepared for BXPE (the “Prospectus”). An investment in BXPE involves subscribing to shares of a collective investment and not of a given underlying asset.
“Strategy Breakdown” weighting is measured as the asset value of each of Blackstone’s underlying business strategies (Corporate PE, Opportunistic, Growth and Secondaries) divided by the asset value of BXPE’s investments, excluding Debt & Other Securities. Totals may not sum due to rounding. There is no generally accepted definition of the following strategy classifications and the use of different criteria in selecting investments could result in materially different classifications from those shown herein. All determinations are made by Blackstone in its sole discretion. Investments are classified as Corporate PE if they are (i) minority or majority common equity investments in Operating Companies; or (ii) equity-linked securities (e.g., warrants, preferred convertibles) with uncapped upside (e.g., where the common equity component is a meaningful percentage of the investment amount or the returns from the equity-linked component account for a meaningful percentage of the underwritten returns).Investments are classified as Opportunistic if they are (i) preferred equity with capped upside; (ii) corporate debt with equity-like returns (based on prevailing market conditions at the time of underwriting) but capped upside; (iii) structured investments in non-Operating Companies (e.g., forward flow, asset backed, MSRs, royalties, loan or credit pools); or (iv) collateralized debt with first loss equity exposure. Investments are classified as Growth if they are minority or majority common equity investments in operating companies with a meaningful amount of top-line growth in the following sectors: enterprise solutions, consumer tech, consumer, healthcare, financial services, and life sciences. The financing of life sciences products in late-stage development, and any equity investments in life sciences companies, are also classified as Growth investments. Investments are classified as Secondaries if they are (i) acquisition of limited partner interests or (ii) passive equity co-investments sourced by Blackstone Strategic Partners. Investments are classified as Debt & Other Securities if they are used to facilitate capital deployment and provide a potential source of liquidity, including but not limited to, investment-grade debt, leveraged loans, and high-yield bonds. Corporate PE, Opportunistic, Growth, and Secondaries listed above are also referenced herein as “Private Equity Investments.” A portion of BXPE is held in Debt and Other Securities for income, capital deployment, and liquidity management.
Represents BXPE’s allocation of 95 closed Private Equity investments as of October 31, 2025.
“Thematic Breakdown” weighting is measured as the asset value of each sector category divided by the asset value of BXPE’s investments, excluding Debt & Other Securities. Totals may not sum due to rounding. Sector classifications are based on BXPE’s internal review and have been qualified to meaningfully distinguish among various investment types and may not be representative of all investments in a given sector. All determinations are made by BXPE in its sole discretion. Excludes diversified secondaries portfolios as data is not available.
“Regional Breakdown” weighting is measured as the asset value of each region category divided by the asset value of BXPE’s investments, excluding Debt & Other Securities and fund commitments to diversified Secondaries funds. Totals may not sum due to rounding. Region based on where each investment has its principal place of business. Excludes diversified secondaries portfolios as data is not available.
“Portfolio Breakdown” is calculated as the value of each asset type divided by the asset value of all BXPE investments.
The investment examples presented herein are provided for illustrative purposes only and reflect an objective, non-performance based standard of showing invested and committed deals in the last twelve months that illustrate BXPE’s high-conviction themes and the types of thematic investments that may be made by BXPE in the future. The selection of investments herein is based on audience familiarity of widely known brands that have sizeable investments or commitments within BXPE’s portfolio, as of October 31, 2025 (to the extent that BXPE is authorized to disclose such positions).
Adevinta is the world’s largest online classifieds company (excluding China) based on revenues generated from online classifieds listings and advertisements, operating digital marketplaces in 10 countries.
Businesswire as of December 5, 2024.
Bain analysis as of April 2024. HQ in France; manufacturing sites in Italy, China, and United States.
Entrepreneur Magazine 2024. Franchise 500 Ranking.
World Culinary Awards 2024 Best Restaurant.
Largest by number of live theater venues.
As of October 2023. Based on Blackstone’s internal review of the number of live theater venues of competitive theater operating groups globally, which may not be representative of all in the category or sector.
Bloomberg as of October 2024.
Moderna. Research –mRNA Pipeline. Accessed March 2024. / Pharmaceutical Technology. Moderna leads the development of mRNA vaccines in infectious diseases. January 29, 2024.
Blackstone Internal Analysis as of June 2025.